Protagen Receives CE Mark for BICD2 Systemic Sclerosis Marker | GenomeWeb

NEW YORK (GenomeWeb) – Protagen said today that it has received the CE mark for its Multilisa BICD2 test for diagnosing systemic sclerosis, enabling the firm to market the test in the European Union and other countries that accept the CE mark.

The announcement follows the release last month of Protagen's CE-marked Multilisa CENP-B and Multilisa Scl70 assays, giving the company what CEO Stefan Müllner called "a comprehensive assay portfolio for the improvement of [systemic sclerosis] diagnosis and patient care."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.